Primary prevention of diabetes mellitus type 2;Primärprävention beim diabetes mellitus typ 2

Internist

Volumn 45, Issue SUPPL. 1, 2004, Pages

  Gallwitz, B ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Acarbose; Diabetes prevention; Impaired glucose tolerance; Life style intervention; Metformin

Indexed keywords

ACARBOSE; METFORMIN; STATINE DERIVATIVE;

DRUG EFFECT; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INCIDENCE; LIFESTYLE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIMARY PREVENTION; PROSPECTIVE STUDY; REVIEW; RISK ASSESSMENT; RISK FACTOR; SOCIOECONOMICS; TREATMENT OUTCOME;

EID: 3142698266     PISSN: 00209554     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (23)

1. Zimmet P, Alberti KG, Shaw J (2001) Global and societal implications of the diabetes epidemic. Nature 414: 782-787
2. Sinha R, Fisch G,Teague B et al. (2002) Prevalence of impaired glucose tolerance among children and adolescents with marked obesity. N Engl J Med 346: 802-810
3. Balkau B, Shipley M, Jarrett RJ et al. (1998) High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men. 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study. Diabetes Care 21: 360-367
4. Malmberg K, Yusuf S, Gerstein HC et al. (2000) Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry. Circulation 102: 1014-1019
5. Hanefeld M, Koehler C, Henkel E, Fuecker K, Schaper F, Temelkova-Kurktschiev T (2000) Post-challenge hyperglycaemia relates more strongly than fasting hyperglycaemia with carotid intima-media thickness: the RIAD Study. Risk Factors in Impaired Glucose Tolerance for Atherosclerosis and Diabetes. Diabet Med 17: 835-840
6. Chiasson JL, Gomis R, Hanefeld M, Josse RG, Karasik A, Laakso M (1998) The STOP-NIDDM Trial: an international study on the efficacy of an alpha-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data. Study to Prevent Non-Insulin-Dependent Diabetes Mellitus. Diabetes Care 21: 1720-1725
7. Meier JJ, Deifuss S, Gallwitz B, Klamann A, Schmiegel W, Nauck MA (2002) [Influence of impaired glucose tolerance on long-term survival after acute myocardial infarction]. Dtsch Med Wochenschr 127: 1123-1129
8. The DECODE study group: Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe; European Diabetes Epidemiology Group (1999) Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 354: 617-621
9. The Diabetes Prevention Program Research Group (2000) The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care 23: 1619-1629
10. Harris MI, Klein R, Welborn TA, Knuiman MW (1992) Onset of NIDDM occurs at least 4-7 yr before clinical diagnosis. Diabetes Care 15: 815-819
11. Sherwin RS, Anderson RM, Buse JB et al. (2002) The prevention or delay of type 2 diabetes. Diabetes Care 25: 742-749
12. Norhammar A, Tenerz A, Nilsson G et al. (2002) Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet 359: 2140-2144
13. de Vegt F, Dekker JM, Jager A et al. (2001) Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population: The Hoorn Study. JAMA 285: 2109-2113
14. The DECODE-study group: Diabetes Epidemiology: Collaborative analysis of Diagnostic Criteria in Europe; European Diabetes Epidemiology Group (1999) Is fasting glucose sufficient to define diabetes? Epidemiological data from 20 European studies. Diabetologia 42: 647-654
15. Vaccaro O, Ruffa G, Imperatore G, Iovino V, Rivellese AA, Riccardi G (1999) Risk of diabetes in the new diagnostic category of impaired fasting glucose: a prospective analysis. Diabetes Care 22: 1490-1493
16. Jarrett RJ, Keen H, McCartney P (1984) The Whitehall Study: ten year follow-up report on men with impaired glucose tolerance with reference to worsening to diabetes and predictors of death. Diabet Med 1: 279-283
17. Pan XR, Li GW, Hu YH et al. (1997) Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 20: 537-544
18. Sartor G, Schersten B, Carlstrom S, Melander A, Norden A, Persson G (1980) Ten-year follow-up of subjects with impaired glucose tolerance: prevention of diabetes by tolbutamide and diet regulation. Diabetes 29: 41-49
19. Tuomilehto J, Lindstrom J, Eriksson JG et al. (2001) Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344: 1343-1350
20. Knowler WC, Barrett-Connor E, Fowler SE et al. (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346: 393-403
21. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M (2002) Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 359: 2072-2077
22. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M (2003) Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 290: 486-494
23. Emslie-Smith AM, Boyle DI, Evans JM, Sullivan F, Morris AD (2001) Contraindications to metformin therapy in patients with Type 2 diabetes - a population-based study of adherence to prescribing guidelines. Diabet Med 18: 483-488